North Central Cancer Treatment Group (NCCTG) N0432: Phase II trial of docetaxel with capecitabine and bevacizumab as first-line chemotherapy for patients with metastatic breast cancer

Annals of Oncology

Volumn 21, Issue 2, 2009, Pages 269-274

  Perez, E A ^a   Hillman, D W ^b   Dentchev, T ^c   Le Lindqwister, N A ^d   Geeraerts, L H ^e   Fitch, T R ^f   Liu, H ^b   Graham, D L ^g   Kahanic, S P ^h   Gross, H M ⁱ   Patel, T A ^a   Palmieri, F M ^a   Dueck, A C ^f  

^a MAYO CLINIC   (United States)

^b MAYO CLINIC   (United States)

^c ALTRU HEALTH SYSTEM   (United States)

^d Illinois Oncology Research Association Community Clinical Oncology Program IL Cancer Care   (United States)

^e MeritCare Hospital   (United States)

^f MAYO CLINIC   (United States)

^g Carle Cancer Center   (United States)

^h Siouxland Hematology Oncology Associates   (United States)

ⁱ Dayton Clinical Oncology Program CCOP Hematology and Oncology of Dayton Inc   (United States)

Author keywords

Bevacizumab; Capecitabine; Chemotherapy; Docetaxel

Indexed keywords

ANTHRACYCLINE; BEVACIZUMAB; CAPECITABINE; DEXAMETHASONE; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; TAXANE DERIVATIVE;

ADJUVANT THERAPY; ADULT; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE FREE SURVIVAL; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; EPIPHORA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HAND FOOT SYNDROME; HEMATOLOGIC DISEASE; HUMAN; INFECTION; LEUKOPENIA; MALE; METASTASIS POTENTIAL; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAIL DISEASE; NAUSEA; NEUROLOGIC DISEASE; NEUROPATHY; NEUTROPENIA; OVERALL SURVIVAL; PHARYNGITIS; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SKIN DISEASE; STOMATITIS; VOMITING; AGED; BLEEDING; DRUG RESPONSE; EVENING DOSAGE; GASTROINTESTINAL HEMORRHAGE; HYPERTENSION; MORNING DOSAGE; MOTOR NEUROPATHY; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; SENSORY NEUROPATHY; SKIN MANIFESTATION; THROMBOSIS;

EID: 77949503823     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdp512     Document Type: Article

References (27)

1. Cardoso F, Di LA, Lohrisch C et al. Second and subsequent lines of chemotherapy for metastatic breast cancer: what did we learn in the last two decades? Ann Oncol 2002; 13: 197-207.
2. Jemal A et al. Cancer statistics 2009. J Clin Oncol 2009; 59(4): 225-249.
3. Piccart-Gebhart MJ, Burzykowski T, Buyse M et al. Taxanes alone or in combination with anthracyclines as first-line therapy of patients with metastatic breast cancer. J Clin Oncol 2008; 26: 1980-1986.
4. O'Shaughnessy J, Miles D, Vukelja S et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol 2002; 20: 2812-2823.
5. Verma S, Clemons M. First-line treatment options for patients with HER-2 negative metastatic breast cancer: the impact of modern adjuvant chemotherapy. Oncologist 2007; 12: 785-797.
6. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100: 57-70.
7. Ferrara N, Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr Rev 1997; 18: 4-25.
8. Dvorak HF, Nagy JA, Feng D et al. Vascular permeability factor/vascular endothelial growth factor and the significance of microvascular hyperpermeability in angiogenesis. Curr Top Microbiol Immunol 1999; 237: 97-132.
9. Mercurio AM, Lipscomb EA, Bachelder RE. Non-angiogenic functions of VEGF in breast cancer. J Mammary Gland Biol Neoplasia 2005; 10: 283-290.
10. Gasparini G, Toi M, Miceli R et al. Clinical relevance of vascular endothelial growth factor and thymidine phosphorylase in patients with node-positive breast cancer treated with either adjuvant chemotherapy or hormone therapy. Cancer J Sci Am 1999; 5: 101-111.
11. Linderholm B, Tavelin B, Grankvist K et al. Vascular endothelial growth factor is of high prognostic value in node-negative breast carcinoma. J Clin Oncol 1998; 16: 3121-3128.
12. Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335-2342.
13. Sandler A, Gray R, Perry MC et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006; 355: 2542-2550.
14. Motzer RJ, Hutson TE, Tomczak P et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007; 356: 115-124.
15. Escudier B, Eisen T, Stadler WM et al. Sorafenib in advanced clear-cell renal- cell carcinoma. N Engl J Med 2007; 356: 125-134.
16. Bukowski RM, Kabbinavar FF, Figlin RA et al. Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer. J Clin Oncol 2007; 25: 4536-4541.
17. Miller K, Wang M, Gralow J et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007; 357: 2666-2676.
18. Miles D, Chan A, Romieu G et al. Randomized, double-blind, placebo-controlled, phase III study of bevacizumab with docetaxel or docetaxel with placebo as first-line therapy for patients with locally recurrent or metastatic breast cancer (mBC): AVADO. J Clin Oncol 2008; 26(15s): 1008s (Abstr LBA1011).
19. Perez EA. Novel enhanced delivery taxanes: an update. Semin Oncol 2007; 34(3) (Suppl): 1-5.
20. Mrozek E, Ramaswamy B, Young D et al. Phase II study of weekly docetaxel and capecitabine in patients with metastatic breast cancer. Clin Breast Cancer 2006; 7: 141-145.
21. Blum JL, Dees EC, Chacko A et al. Phase II trial of capecitabine and weekly paclitaxel as first-line therapy for metastatic breast cancer. J Clin Oncol 2006; 24: 4384-4390.
22. Lueck H, von Minckwitz G, Du Bois A et al. Epirubicin/paclitaxel (EP) vs. capecitabine/paclitaxel (XP) in first-line metastatic breast cancer (MBC): a prospective, randomized multicentre phase III study of the AGO breast cancer study group. J Clin Oncol 2006; 24(18s): 7s (Abstr 517).
23. Miller KD, Chap LI, Holmes FA et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 2005; 23: 792-799.
24. Sledge G, Miller K, Moisa C et al. Safety and efficacy of capecitabine (C) plus bevacizumab (B) as first-line in metastatic breast cancer. J Clin Oncol 2007; 25(18s): 35s (Abstr 1013).
25. Robert NJ, Dieras V, Glaspy J et al. RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab (B) for first-line treatment of HER2-negative locally recurrent or metastatic breast cancer (MBC). J Clin Oncol 2009; 27(15s): 42s (Abstr 1005).
26. Leonard R, O'Shaughnessy J, Vukelja S et al. Detailed analysis of a randomized phase III trial: can the tolerability of capecitabine plus docetaxel be improved without compromising its survival advantage? Ann Oncol 2006; 17: 1379-1385.
27. Lebowitz PF, Eng-Wong J, Swain SM et al. A phase II trial of neoadjuvant docetaxel and capecitabine for locally advanced breast cancer. Clin Cancer Res 2004; 10: 6764-6769.